Market Overview

FDA Accepts Biologics License Application for PaxVax's Single-Dose Oral Cholera Vaccine Vaxchora


PaxVax Inc. today announced that the U.S. Food and Drug Administration
(FDA) has accepted for filing and review the Biologics License
Application (BLA) for its affiliate PaxVax Bermuda Ltd.'s single-dose
oral cholera vaccine Vaxchora™. PaxVax also announced today that the FDA
has granted Vaxchora priority review status. If licensed, Vaxchora would
be the only vaccine in the U.S. against cholera and PaxVax's second
FDA-licensed vaccine after Vivotif® (typhoid fever vaccine).

"Travelers residing in the U.S. currently have very few options to
protect themselves against cholera when going abroad, and we are pleased
with the progress we are making

See full press release

Posted-In: News FDA Press Releases


Related Articles

View Comments and Join the Discussion!

Argus Upgrades Chevron To Buy; Volatility In Oil Creates Better Entry Point

Early Global News: Records Set In The Airline Sector, Alibaba To Expand In Russia, And More